Top

Published in:

01-04-2010 | Special Feature

Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer

Author: Yoshio Miki

Published in: Breast Cancer | Issue 2/2010

Abstract

Development of a clear index to select drugs, i.e., accurate prediction of drug sensitivity, is important not only to obtain the maximum therapeutic effects of drugs, but also realize personalized medicine (tailor-made medicine). With the recent advancement in genome science represented by microarrays, molecular-level elucidation of many diseases including cancers has been progressing. It has been clarified that molecular information, such as gene expression profiles of cancer cells and gene polymorphisms in individual patients, affects not only cancer development and progression, but also therapeutic and adverse effects. The establishment of a therapeutic method by clinical application of this information has been progressing, in which the therapeutic effects of drugs are accurately predicted, and the maximum effects are obtained corresponding to cancer properties and patients’ characteristics.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. In: 10th St. Gallen conference. Ann Oncol. 2007;18:1133–44.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–9.CrossRefPubMed

Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 2005;23:422–31.CrossRefPubMed

Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004;22:2284–93.CrossRefPubMed

Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24:4236–44.CrossRefPubMed

Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 2001;61:6474–9.PubMed

Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004;13:3029–43.CrossRefPubMed

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2009;113:275–83.CrossRefPubMed

Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, et al. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol. 2009;34:361–70.PubMed

10.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.CrossRefPubMed

11.

Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006;24:1665–71.CrossRefPubMed

12.

Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–7.CrossRefPubMed

13.

Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999;96:9212–7.CrossRefPubMed

14.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.CrossRefPubMed

15.

Massagué J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007;356:294–7.CrossRefPubMed

16.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.CrossRefPubMed

17.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.CrossRefPubMed

18.

van‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRef

19.

van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.CrossRefPubMed

20.

Wu RZ, Bailey SN, Sabatini DM. Cell-biological applications of transfected-cell microarrays. Trends Cell Biol. 2002;12:485–8.CrossRefPubMed

21.

Vanhecke D, Janitz M. High-throughput gene silencing using cell arrays. Oncogene. 2004;23:8353–8.CrossRefPubMed

22.

Fujita S, Ota E, Sasaki C, Takano K, Miyake M, Miyake J. Highly efficient reverse transfection with siRNA in multiple wells of microtiter plates. J Biosci Bioeng. 2007;104:329–33.CrossRefPubMed

23.

Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007;446:815–9.CrossRefPubMed

24.

Nagasaki K, Miki Y. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2008;15:117–20.CrossRefPubMed

Title: Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer
Author: Yoshio Miki
Publication date: 01-04-2010
Publisher: Springer Japan
Published in: Breast Cancer / Issue 2/2010
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-009-0180-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Ultrasound findings and histological features of ductal carcinoma in situ detected by ultrasound examination alone

Intracystic invasive papillary carcinoma of the male breast with analyses of loss of heterozygosity on chromosome 16q

Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG)

Breast cancer research from bench to bedside

Breast cancer stem cells

Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland

Keynote webinar | Spotlight on antibody–drug conjugates in cancer